Summary

The phase 2b results of the randomized, double-blind, placebo-controlled TIME study provide evidence of activity with TG4010, a therapeutic cancer vaccine, when added to first-line chemotherapy for stage IV non–small cell lung cancer, especially for nonsquamous histology and low levels of triple-positive activated lymphocytes. These data suggest that normal levels of triple-positive activated lymphocytes may be a predictive biomarker of TG4010 efficacy.